EP2293071A1 — Biomarker for colorectal cancer
Assigned to Universitaet zu Koeln · Expires 2011-03-09 · 15y expired
What this patent protects
The present invention relates to new methods for predicting the clinical outcome or determining the treatment course in a subject afflicted with colorectal cancer and for monitoring the progression of colorectal cancer in a subject. Moreover, the present invention relates to a me…
USPTO Abstract
The present invention relates to new methods for predicting the clinical outcome or determining the treatment course in a subject afflicted with colorectal cancer and for monitoring the progression of colorectal cancer in a subject. Moreover, the present invention relates to a method for stratification of therapy regimen of a subject afflicted with soild tumor entities, such as colorectal cancer, for determining its susceptibility to the treatment with an inhibitor of angiogenesis. Further, the present invention relates to kits allowing performance of the above methods. In particular, the present invention is based on the finding that determining the level or amount of angiopoietin-2 protein in a sample of a subject is useful for conducting the above referenced methods.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.